Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China’s National Medical Products Administration (NMPA) has approved the initiation of a clinical trial of SHR‑2005 injection, in combination with SHR‑1501 for injection ± adebrelimab injection ± BCG, for the treatment of bladder cancer. SHR‑2005 is an innovative antitumor drug independently developed by Hengrui Pharma, with no similar drug currently marketed in China or internationally.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial initiation (IND) |
| Lead Product | SHR‑2005 injection — innovative antitumor drug for bladder cancer |
| Trial Regimen | SHR‑2005 + SHR‑1501 ± adebrelimab ± BCG |
| Indication | Bladder cancer |
| Announcement Date | 26 Oct 2026 |
| Differentiation | First-of-kind asset — no similar drug marketed in China or globally |
Drug Profile & Mechanism of Action
- SHR‑2005 (Lead Asset): Independently developed innovative antitumor injection intended for bladder cancer; no comparable product is currently marketed in China or internationally, positioning it as a potential first-in-class therapy.
- SHR‑1501 (IL‑15 Fusion Protein): An interleukin‑15 (IL‑15) fusion protein with proprietary intellectual property rights, designed to stimulate the proliferation of T cells, B cells, and NK cells to exert antitumor effects. Its overseas counterpart, nogapendekin alfa inbakicept (brand name: Anktiva), is already approved for marketing in the United States, while no product targeting the same mechanism has been approved in China — leaving SHR‑1501 with a clear domestic whitespace.
- Adebrelimab (Anti‑PD‑L1 Backbone): A humanized anti‑PD‑L1 monoclonal antibody independently developed by Hengrui and already approved in China for two indications: (1) with carboplatin and etoposide for first-line extensive-stage small cell lung cancer (ES‑SCLC); and (2) as neoadjuvant therapy with platinum-containing chemotherapy, followed by monotherapy adjuvant treatment after surgery, for adults with resectable stage II, IIIA and IIIB non-small cell lung cancer (NSCLC) without known EGFR mutations or ALK rearrangements.
- BCG Component: The trial’s optional BCG (bacillus Calmette‑Guérin) arm reflects the standard intravesical immunotherapy backbone in bladder cancer management, allowing evaluation of the novel combination both with and without established local therapy.
Market Impact & Outlook
- Bladder Cancer Landscape in China: Bladder cancer ranks among the most common urologic malignancies in China, with high recurrence rates in early-stage disease and limited systemic options in advanced settings — underscoring the value of novel mechanistic approaches.
- Combination Strategy: The multi-arm design (SHR‑2005 + IL‑15 agonist ± PD‑L1 blockade ± BCG) mirrors Hengrui’s platform approach of stacking differentiated innate and adaptive immune activation, with potential readouts across both non-muscle-invasive and muscle-invasive disease settings.
- IL‑15 Class Validation: With Anktiva commercially approved in the US, the IL‑15 agonist class carries clinical validation — and SHR‑1501 could become the first such agent to reach Chinese patients, given no same-target product is approved domestically.
- Pipeline Depth: Adding an oncology first-of-kind asset to a portfolio already anchored by approved checkpoints inhibitors reinforces Hengrui’s position as China’s most diversified innovative pharma in immuno-oncology.
- Next Steps: Trial design details, patient enrollment scope, and timelines were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding SHR‑2005, SHR‑1501, and adebrelimab, including their clinical development for bladder cancer. Clinical trial initiation does not guarantee future approval; actual outcomes may differ due to risks including trial execution, safety and efficacy results, regulatory review, and competitive dynamics.-Fineline Info & Tech
